Photo by JESHOOTS.com on Pexels.com

Proteostasis Therapeutics Stock Price Skyrockets From Positive FDA Phase 1 Results

Proteostasis Therapeutics Announces Positive Preliminary FDA Phase 1 Results

(By Glenford S Robinson)

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), stock price skyrocketed 300% today, October 18, 2017 on positive Phase 1 study news from the Food and Drug Administration (FDA), which stated that the company’s proprietary doublet PTI-801 and PTI-808 cystic fibrosis research medicines have proven safe at the dosage level administered to research volunteers. The study volunteers consist of 20 to 100 individuals, which includes healthy people and those with the disease.

Proteostasis Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company focused on developing therapies effective against cystic fibrosis (CF), a diseased caused by the dysfunctional processing of protein in the human body.

Armed with over 450 issued patents and a topnotch group of research scientists in technology, pharmaceuticals, and healthcare, PTI is confident that it can support its claim as the Inventor of Digital Medicine. In fact, a positive Phase 1 result of its cystic fibrosis research drug study is a strong indication that the company is capable of supporting such claim, as the undisputed Inventor of Digital Medicine.

The company claimed to be the Inventor of Digital Medicine, simply because it has developed a new category of pharmaceuticals that measures the effectiveness of medication treatment, help physicians in improving clinical outcomes and thus, help patients accomplish health goals.

Proteostasis Therapeutics plans to bring its new digital solution to healthcare providers by coordinating its efforts with leading health systems and pharmaceutical companies which will increase access to better insights, optimized therapies, and reduced costs.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved.

Check Also

FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through their Individual Diabetes Management Devices

“Diabetes is a complicated disease that requires close monitoring and carefully tailored treatments. We’ve heard from the patient community that having the ability to customize their own diabetes management devices is important to them. Advances in digital health make more tailored approaches to diabetes care possible,” said FDA Commissioner Scott Gottlieb, M.D. “The marketing authorization of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualized diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently. Because the FDA’s action creates a new regulatory classification, future ACE insulin pumps will be able to go through the more efficient 510(k) review process, helping to advance this innovative technology. We’re committed to advancing new ways to accelerate the development of innovations that can improve patient care while strengthening our pre- and post-market tools for determining the safety and effectiveness of these new technologies.

California Jury finds Johnson & Johnson Baby Powder Contained Asbestos, was Defective, and its Risks were “Known or Knowable” to the Company

For its part, Reuters has stood by its reporting, citing multiple tests from 1971 to the early 2000s finding asbestos in Johnson's Baby Powder and talc from mines which supplied J&J.

Teva Pharmaceutical Stock (TEVA) Trading Higher Today on FDA Approval of Its Seizure Drug Sabril for Adults and Pediatric Epilepsy Patients

Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness. Typically, complex partial seizures last between 30 and 90 seconds, and are often followed by a period of disorientation, confusion and/or fatigue.

photos by pexels.com

Canopy Growth Receives New York State Hemp Licence and Will Establish U.S.-Based Commercial Operations

"Canopy Growth's $100-$150 million investment in the Southern Tier is a true win-win - for Canopy Growth, who will be positioned at the forefront of Upstate New York's industrial hemp revolution, and for the Southern Tier's economy and farmers, which will receive a major shot in the arm in new good-paying jobs. I fought so hard to strip the burdensome federal regulations from industrial hemp in our Industrial Hemp Farming Act of 2018, which was recently included in the Farm Bill, because I knew how much it could mean to the Southern Tier, and this investment proves it. I'm so pleased that Canopy Growth is joining my efforts to make the Southern Tier the Silicon Valley of industrial hemp production and research and will keep pushing to see industrial hemp become a true cash crop in the region," said Senator Schumer.

rawpixel.com photo

The Food and Drug Administration (FDA) Just Approved a Diagnostic Test to Assist Healthcare Providers in Measuring Nutrients in Breast Milk

The FDA reviewed data submitted by the sponsor of 112 samples of human milk to analyze the performance of the device. For the study, the sponsor tested the same 112 samples in the machine and compared them to the expected true values obtained by independent methods; both systems provided similar results for each test. The data showed that the Miris Human Milk Analyzer test was effective at determining levels of protein, fat and carbohydrate in the milk. There may be conditions that limit the information available from the Miris Human Milk Analyzer. For example, certain medications that a nursing mother may be taking could interfere with the test’s ability to accurately measure nutrient levels in breast milk.

What About the New 52-Week High Mark for a Stock?

For the short-term minded trader who elects to buy the stock as a result of its 52-week outstanding performance, short-term trouble could be on the horizon. The main reason why there could be trouble is because professional and institutional traders use a stock’s 52-week high mark has a take-profit point where they lock in their gains accrued over the past year.

Meridian Bioscience, Inc., Stock (VIVO) in Spot Light Today After FDA Granted Marketing Authorization of Alethia CMV Assay Test System to the Company

According to the Centers for Disease Control and Prevention, more than half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms of infection. However, CMV infection can cause serious health problems for people with weakened immune systems and for some newborns.

%d bloggers like this: